منابع مشابه
Tisssue factor and factor viia cross-species compatibility Tisssue factor and factor viia cross-species compatibility
1. Astract 2. Introduction 3. TF and FVIIa 3.1. Purification, cloning and expression of TF 3.2. TF structure and function 3.3. Purification, cloning and expression of FVII 3.4. FVIIa structure and function 3.5. Interaction of FVIIa with TF 3.6. Binding of human FVIIa to sTF, lipidated TF and cell surface TF 3.6.1. FVIIa binding to sTF 3.6.2. FVIIa binding to lipidated TF and to cell surface TF ...
متن کاملBinding of factor VIIa to tissue factor permits rapid antithrombin III/heparin inhibition of factor VIIa.
Because free factor VIIa is inactivated only very slowly by a plasma concentration of antithrombin III (AT III) even in the presence of heparin, it has been assumed that AT III plays no significant role in regulating the initiation of tissue factor-dependent blood coagulation. However, in the present study, we present evidence that factor VIIa bound to tissue factor, unlike free factor VIIa, is...
متن کاملInhibitors of Factor VIIa/tissue factor.
The formation of the proteolytic complex composed of the serine protease Factor VIIa and the cell-associated glycoprotein tissue factor (FVIIa/TF) initiates a cascade of amplified zymogen activation reactions leading to thrombus formation. The critical role of the coagulation cascade in pathological thrombosis has been the basis for significant efforts to design selective inhibitors of the prot...
متن کاملFactor VIIa gets even bigger.
Thromb Haemost 2008; 99: 653–654 Since its introduction onto the market in 1996, recombinant factor VIIa (rFVIIa: NovoSeven®; Niastase®; produced by Novo Nordisk, Baegsvaerd, Denmark) has become an increasingly important therapeutic option for physicians caring for haemophilia patients with inhibitors. Both because of its short terminal half-life of approximately three hours (1, 2), and the way...
متن کاملTissue factor in brain is not saturated with factor VIIa: implications for factor VIIa dosing in intracerebral hemorrhage.
The recent commentary by Dr Torbey on “Intracerebral Hemorrhage: What’s Next?”1 has prompted us to share some data and thoughts on the use of activated factor VII (FVIIa, NovoSeven, Novo Nordisk A/S) in the management of intracerebral hemorrhage. FVIIa is approved to promote hemostasis in hemophiliacs with inhibitors. Studies have also suggested that it promotes hemostasis in nonhemophilic pati...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Japanese Journal of Thrombosis and Hemostasis
سال: 2009
ISSN: 1880-8808,0915-7441
DOI: 10.2491/jjsth.20.571